Transbronchial lung cryobiopsy (TBLC) for diagnosis of interstitial lung diseases (ILD)

COLDICE study results and latest CHEST guidelines

Background

The gold standard for diagnosis and classification of ILD includes HRCT (high resolution chest tomography) and a multidisciplinary diagnosis (MDD), a decision-making process involving clinicians, radiologists and pathologists. But in up to 30–40% of cases, definite diagnosis specifying the ILD is not possible by this strategy alone and thus, histological findings are required.

Method

In this comparative, multicenter, prospective, investigator-initiated study, diagnostic accuracy of TBLC and SLB was compared in 65 patients, using biopsy specimens obtained sequentially from the same patient under one anesthesia.

For TBLC, 1.9 mm or 2.4 mm reusable cryoprobes (Erbe Elektromedizin, Tübingen, Germany) were used and 4 to 7 biopsy specimens were obtained from each patient. Following TBLC, two SLBs were taken from the equivalent lobes.

Challenges and goals

Surgical lung biopsy (SLB) until now has been the gold standard recommended in different guidelines, but is associated with significant morbidity, with complications including postoperative pneumothorax, pneumonia and respiratory failure, as well as significant mortality, indicated at 1.7%. Given these risks and the often detrimental state of suspected ILD patients, reported SLB rates in ILD are lower than estimated necessary and in 2016 reached only 8% in Europe.

Consequently, transbronchial lung cryobiopsy (TBLC), a minimal invasive technique allowing biopsy without major surgery, is increasingly used in diagnosis of ILD.

The COLDICE study (Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease) has addressed both approaches.

Design of the COLDICE study

- 65 patients
  - TBLC
    - Diagnosis based on pathology
  - SLB
    - Diagnosis based on MDD
- Results
  - 70.8% overall agreement
  - 76.9% overall agreement
  - 95% agreement for high-confidence or definite diagnoses
Results and key findings

High levels of agreement between TBLC and SLB obtained sequentially from the same patients were shown. The TBLC MDD diagnoses made with high confidence were particularly reliable, showing excellent concordance with SLB MDD diagnoses; in these cases SLB added minimal diagnostic value. For unclassifiable or low confidence TBLC MDD diagnoses, although the agreement with SLB MDD was lower, SLB provided an alternative definite or high confidence diagnosis in only a minority.

Implications and recommendations

Based on the results of the COLDICE study, minimally-invasive TBLC is therefore recommended for experienced bronchoscopists.\(^2,7,9,10\).

- As the first option in patients with ILD requiring lung biopsy
- Limiting the necessity for surgical lung biopsy to those patients in which cryobiopsy is non-diagnostic.

TBLC specimens provide data that are:

- Useful and reliable
- Particularly when high-confidence patterns are reported
- Associated with a lower mortality rate of 0.2 % compared to 1.7 % associated with VATS.\(^3,5\)

This high-quality study revealed that diagnostic yield between TBLC and SLB is comparable in both cases; with histopathological assessment alone and with MDD diagnoses. These results support the clinical utility of TBLC as a valid first-line minimally-invasive diagnostic tool for patients with ILD deemed to require lung biopsy.\(^7\)

This recommendation has also been integrated in the newest "CHEST Guideline and Expert panel report" (2019) on TBLC for the diagnosis of ILD, which suggests that TBLC can be used to obtain histopathological evidence for MDD diagnosis.\(^12\). Specifically, Maldonado and colleagues phrase the following recommendations:

1. In patients with suspected ILD, we suggest that TBLC can be used to provide histopathologic findings for multidisciplinary discussion (MDD) diagnosis.
2. In patients with suspected ILD undergoing TBLC, we suggest biopsy of at least two different sites (either different segments in the same lobe or different lobes).
3. In patients with suspected ILD undergoing TBLC, we suggest biopsy with the tip of the cryoprobe located 1 cm from the pleura.
4. In patients with suspected ILD undergoing TBLC, we suggest the use of fluoroscopy (Ungraded Consensus-Based Statement).
5. In patients with suspected ILD undergoing TBLC, we suggest that TBLC be performed with a bronchial blocker either through an endotracheal tube or rigid bronchoscope.
6. In patients with suspected ILD undergoing TBLC, we suggest the use of a small cryoprobe (1.9 mm) rather than a larger cryoprobe (2.4 mm).
Products

The COLDICE study was performed with the 1.9 mm reusable cryoprobe and the ERBECRYO® 2 system.

Our new portfolio includes three flexible single-use cryoprobes with diameters of 1.1, 1.7 (see pic.) and 2.4 mm. Several advantages are offered by the new portfolio such as enhanced ergonomics and handling characteristics through patented elements15,16.

The consistent technical performance supports

- Consistent target tissue effects
- Superior reproducibility
- Improved standardization13,14

Besides tissue biopsies, our flexible single-use cryoprobes allow further clinical applications. These include tissue de-vitalization and the extraction of tissue tumors, as well as foreign bodies.

84% of all users believe, that single-use cryoprobes support the standardization of flexible cryo applications.17

References

9 Internal measurements D144193
10 Internal test report D147320
11 Internal measurements D099747
12 Usability report D129848
13 User acceptance test report D162230

Transbronchial cryobiopsy under fluoroscopic guidance
Important Information
We have prepared this document with care. Nonetheless, we cannot completely rule out errors in this document.

The information, recommendations and other data ("Information") contained in this document reflect our state of knowledge and the state of science and technology at the time of preparing the document. The information is of a general nature, non-binding and serves solely for general information purposes and does not represent instructions for use or notes on application.

The information and recommendations contained in this document do not constitute any legal obligations by Erbe Elektromedizin GmbH as well as their associated companies ("Erbe") or any other claims against Erbe. The information does not represent a guarantee or other quality statement, these require the express contractual arrangement with Erbe in individual cases.

Erbe shall not be liable for any type of damage resulting from following information given in this document, regardless of the legal reason for liability.

Every user of an Erbe product is responsible for checking the respective Erbe product for its properties as well as the suitability for the intended type of application or intended purpose in advance. The suitable type of application of the respective Erbe product is given by the user manual and the notes on use for the corresponding Erbe product. The user is obliged to check whether the existing user manual and the notes on use correspond with the status for the specific Erbe product. The devices may only be used according to the user manual and the notes on use.

The information on setting values, application sites, duration of application and the use of the respective Erbe product is based on the clinical experience of physicians independent from Erbe. They represent guidelines which need to be checked by the user for their suitability for the actual planned application. Depending on the circumstances of an actual application case, it may be necessary to deviate from the information provided. The user has to check this on his/her own responsibility in each case when using an Erbe product. We wish to point out that science and technology is constantly subject to new developments arising from research and clinical experience. For this reason it may be necessary for the user to deviate from the information provided in this document.

This document contains information about Erbe products which may possibly not be approved in a specific country. The user of the respective Erbe product is obliged to inform him/herself whether the Erbe product he/she is using is legally approved in his/her country and/or if legal requirements or restrictions for use possibly exist and to which extent.

This document is not intended for users in the USA.